LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Inicio・Lista de Acciones・Lisata Therapeutics

L
Lisata Therapeutics

Cerrado

5.03

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

5.04

Métricas clave
By Trading Economics
Ingresos	410K -4.2M
Margen de beneficio	-6,655.714
Empleados	26

Dividendos
By Dow Jones
Próximas Ganancias	19 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	18M 38M
Apertura anterior	5.03
Cierre anterior	5.03

Lisata Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 mar 2026, 22:42 UTC

Ganancias

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mar 2026, 21:40 UTC

Ganancias

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mar 2026, 23:56 UTC

Charlas de Mercado

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mar 2026, 23:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 mar 2026, 23:42 UTC

Charlas de Mercado

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mar 2026, 23:38 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mar 2026, 23:24 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

17 mar 2026, 23:24 UTC

Charlas de Mercado

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mar 2026, 22:22 UTC

Charlas de Mercado

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mar 2026, 22:20 UTC

Ganancias

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mar 2026, 22:20 UTC

Ganancias

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mar 2026, 22:07 UTC

Ganancias

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mar 2026, 22:05 UTC

Ganancias

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mar 2026, 22:04 UTC

Ganancias

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mar 2026, 22:03 UTC

Ganancias

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mar 2026, 21:26 UTC

Ganancias

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mar 2026, 21:09 UTC

Ganancias

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mar 2026, 21:08 UTC

Ganancias

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mar 2026, 21:08 UTC

Ganancias

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:07 UTC

Ganancias

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:06 UTC

Ganancias

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Net $757.2M >ATD.T

17 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Lisata Therapeutics Esperado

Consenso

By TipRanks

Neutral

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Lisata Therapeutics Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Beneficio antes de impuestos

Ventas

Beneficio operativo

Acerca de Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.